



# Current Research & Developments Status of Chimeric Antigen Receptor (CAR) T-Cell Therapy

August 2018

*Paul Taylor*

Report Code: BIO162A

# Table of Contents

<b>Chapter 1: Introduction</b> .....	<b>1</b>
Scope of the Report .....	1
Methodology and Information Sources .....	2
Primary Data and Information Gathering .....	2
Secondary Data and Information Gathering .....	3
Market Share Analysis and Market Forecast .....	3
Analyst's Credentials .....	5
Related BCC Research Reports .....	5
<b>Chapter 2: Summary and Highlights</b> .....	<b>7</b>
CAR T-Cell Design and Evolution .....	7
FDA Product Approvals .....	7
Market Analysis .....	7
Clinical Applications of CAR T-Cell Therapy .....	10
CARs for Tumors of the Hematopoietic and Lymphoid Tissues .....	10
CAR T-Cell Therapy for Solid Tumors .....	10
Barriers to Research and Product Development .....	10
Clinical Trials .....	11
<b>Chapter 3: Introduction to Chimeric Antigen Receptor (CAR) T-Cell Therapy</b> .....	<b>13</b>
Introduction .....	13
A Brief History of CAR T-Cell Therapy Development .....	14
Antigens .....	15
Exogenous Antigens .....	16
Endogenous Antigens .....	16
Autoantigens .....	16
Tumor Antigens .....	16
Cluster of Differentiation .....	17
Lymphocytes .....	18
B-Cells .....	18
T-Cells .....	19
Adoptive Cell Transfer (ACT) Technologies .....	29
Tumor-Infiltrating Lymphocytes (TILs) .....	30
T-Cell Receptors (TCRs) .....	31
Chimeric Antigen Receptors (CARs) .....	33
<b>Chapter 4: Current Production Methods, Latest Technological Advances and Future Direction</b> .....	<b>41</b>
Production of CAR T-Cells .....	41
Stage 1: Leukapheresis and T-Cell Isolation .....	41
Stage 2: T-Cell Activation, Transduction and Modification of CAR T-Cells .....	42
Stage 3: Expanding Modified CAR T-Cells .....	44
Overcoming CAR T-Cell Manufacturing Challenges .....	45
Latest Advances in Production Processes .....	46
Closed, Automated Production Systems .....	46
End-to-End Production Systems and Solutions .....	47
Key Technologies Used in the Manufacturing Stage .....	47

<b>Chapter 5: Clinical Trial Analysis of CAR T-Cells and Related Technologies .....</b>	<b>61</b>
Introduction .....	61
Clinical Trials Being Conducted Globally .....	61
Distribution of CAR T-Cell Trials in the U.S. ....	69
Distribution of CAR T-Cell Clinical Trials in China.....	75
 <b>Chapter 6: Incidence, Prevalence and Mortality Statistics for Cancer: A Global Summary .....</b>	 <b>85</b>
Cancer: The Disease .....	85
Cancer: A Statistical Analysis of the Disease Incidence and Prevalence.....	86
Incidence and Prevalence Rates for Major Cancer Types .....	86
Global Regional Patterns of Cancer .....	94
Europe .....	94
North America .....	95
Asia-Pacific.....	97
Latin and Central America .....	97
Middle East and Africa .....	98
Global Cancer Burden and Worldwide Cancer Risk Factors .....	98
Tobacco Use and Statistics .....	99
Alcohol Abuse and Cancer Statistics .....	99
Obesity and Cancer Statistics .....	99
Infectious Diseases and Cancer .....	100
Inherited Genes: Diseases and Cancer .....	101
Sun, Ultraviolet Radiation and Cancer .....	101
Hormones and Cancer .....	102
 <b>Chapter 7: Global CAR T-Cell Market Analysis .....</b>	 <b>104</b>
Introduction .....	104
Global CAR T-Cell Market.....	104
Regional CAR T-Cell Market Analysis: North America .....	108
Regional CAR T-Cell Market Analysis: Europe .....	108
Regional CAR T-Cell Market Analysis: Asia-Pacific .....	108
Regional CAR T-Cell Market Analysis: Central and Latin America .....	109
Regional CAR T-Cell Market Analysis: Middle East and Africa .....	109
Global CAR T-Cell Market Share Analysis.....	110
Market Dynamics .....	111
Selected Drivers of the Global CAR T-Cell Market .....	111
Selected Restraints of the Global CAR T-Cell Market.....	112
 <b>Chapter 8: Regulatory and Legislative Requirements for CAR T-Cell and Related Technologies .....</b>	 <b>116</b>
North America.....	116
United States .....	116
Canada .....	118
Europe.....	119
Mutual Recognition Procedure (MRP) .....	120
Decentralized Procedure (DCP) .....	120
Centralized Procedure (CP) .....	121
Asia-Pacific .....	124
Japan.....	124
China.....	126

India.....	130
South Korea.....	135
Central and South America.....	136
Brazil.....	136
Argentina.....	138
Mexico.....	142
Middle East and Africa.....	143
South Africa.....	143
Saudi Arabia.....	145
Published Guidelines on Production and Testing of Cell-Based Therapies.....	149

## Chapter 9: Patent Review/New Developments for Chimeric Antigen Receptors (CARs) ..... 151

Introduction.....	151
Complexities of the Patents and Patent Applications for Biotechnology and Pharmaceutical Companies.....	154
Anticipated Increase in Patent Litigation on Customized Patient Treatments.....	155
Company Specific Intellectual Property and Patent Information.....	157
Amgen.....	157
Avacta Life Sciences Ltd.....	157
Bellicum Pharmaceuticals Inc.....	157
Bluebird Bio.....	158
Celgene Corp.....	160
Cellestis.....	160
Celyad SA.....	162
Editas Medicine Inc.....	162
Eureka Therapeutics Inc.....	165
Gilead Sciences Inc.....	167
iCell Gene Therapeutics.....	170
Juno Therapeutics Inc. (A Celgene Company).....	171
Mustang Bio Inc.....	174
Noile-Immune Biotech.....	175
Novartis AG.....	176

## Chapter 10: Company Profiles ..... 184

### Appendix A ..... 232

Company Addresses and Contact Details.....	232
--	-----

### Appendix B..... 244

Government Regulatory Agencies and Professional Organizations.....	244
--	-----

### Appendix C..... 249

Commonly Used Acronyms Associated with CAR T-Cell Therapy.....	249
--	-----

### Appendix D ..... 255

Recent Patent Applications Filed Related to CAR T-Cell Therapy.....	255
---	-----

### Appendix E..... 275

CAR T-Cell and CD19 Clinical Trials in China.....	275
---	-----

### About BCC Research..... 297

About BCC Research.....	298
-------------------------	-----



# List of Tables

Summary Table A: Global CAR T-Cell Market, by Region, Through 2023 (\$ Millions) .....	8
Summary Table B: Global CAR T-Cell Market, by Product, Through 2023 (\$ Millions).....	9
Table 1 Tumor-Associated Antigens of CAR T-Cell Targets.....	14
Table 2 List of Relevant Human Clusters of Differentiation.....	17
Table 3 Classification of Natural Killer T-Cells.....	28
Table 4 Summary Classification of Tumors of the Hematopoietic and Lymphoid Tissues (%) .....	37
Table 5 Tumor-Associated Antigens of CAR T-Cell Target .....	38
Table 6 Supplementary Components in CAR T-Cell Manufacture .....	42
Table 7 Technologies Used in the Selection, Isolation and Enrichment of Cells During the Manufacture of CAR T-Cells .....	48
Table 8 Technologies Used in the Activation and Simulation of Cells During the Manufacture of CAR T-Cells.....	49
Table 9 Technologies Used in the Gene Transfer and Delivery of Cells During the Manufacture of CAR T-Cells.....	50
Table 10 Gene Transfer and Gene Delivery Technologies Developed by Poseida Therapeutics Inc.....	53
Table 11 Technologies Used in the Expansion and Culture of Cells During the Manufacture of CAR T-Cells .....	56
Table 12 Technologies Used in the Formulation of Cells During the Manufacture of CAR T-Cells .....	57
Table 13 Technologies Used in the Cryopreservation of Cells During the Manufacture of CAR T-Cells ....	58
Table 14 Technologies Used in the Thawing of Cells During the Manufacture of CAR T-Cells.....	59
Table 15 CAR T-Cell Clinical Trial Activity Globally, by Study Location/Region, as of April 26, 2018 (Number).....	64
Table 16 Clinical Trials on CD19 Directed CAR T-Cells in the U.S., as of May 1, 2018 .....	70
Table 17 Examples of Clinical Trials on CD19-Directed CAR T-Cells in China.....	78
Table 18 Examples of Clinical Trials on CAR T-Cells Targeting Non-CD19 Antigens in China.....	80
Table 19 Examples of Clinical Trials on CAR T-Cells for Solid Tumors in China.....	81
Table 20 Clinical Trials on CAR T-Cells with Fourth-Generation CARs in China .....	83
Table 21 Summary Statistics (Global): Estimated Cancer Incidence, Mortality and Five-Year Prevalence, 2012 .....	87
Table 22 Global Estimated Cancer Incidence, Mortality and Five-Year Prevalence in Men and Women Combined, by Cancer Type, 2012 (Number/%) .....	88
Table 23 Global Estimated Cancer Incidence, Mortality and Five-Year Prevalence in Men, by Cancer Type, 2012 (Number/%) .....	90
Table 24 Global Estimated Cancer Incidence, Mortality and Five-Year Prevalence in Women, by Cancer Type, 2012 (Number/%).....	92
Table 25 Estimated Number of New Cancer Cases by Sex in the United States, 2017 (%) .....	95
Table 26 Estimated Number of Deaths from Cancer in the U.S., by Cancer Site and Sex, 2017 (%) .....	96
Table 27 Global CAR T-Cell Market, by Product, 2023 (\$ Millions).....	105
Table 28 Global CAR T-Cell Market, by Region, Through 2023 (\$ Millions).....	106
Table 29 Global CAR T-Cell Market Shares, by Region, 2018 (%) .....	107
Table 30 North American CAR T-Cell Market, Through 2023 (\$ Millions) .....	108
Table 31 European CAR T-Cell Market, Through 2023 (\$ Millions) .....	108
Table 32 Asia-Pacific CAR T-Cell Market, Through 2023 (\$ Millions).....	109
Table 33 Central and Latin American CAR T-Cell Market, Through 2023 (\$ Millions) .....	109
Table 34 Middle East and African CAR T-Cell Market, Through 2023 (\$ Millions) .....	109
Table 35 Global CAR T-Cell Market Shares, by Company, 2018 (%) .....	110
Table 36 Overview of Healthcare in India.....	132

Table 37 Recent Bluebird Bio Patents and Patent Applications, 2010-April 2018 .....	159
Table 38 Editas Medicine Patent Applications, 2010-April 2018.....	163
Table 39 Eureka Therapeutics Patent Applications, 2015-April 2018 .....	165
Table 40 Kite Pharma’s Core Anticancer Technology: Yeda Research and Development Co. Ltd. Patents and Patent Applications, 1993-April 2018 .....	169
Table 41 iCell Gene Therapeutics Patent Applications .....	171
Table 42 Juno Therapeutics Inc. and Memorial Sloan Kettering Patents and Patent Applications.....	173
Table 43 Mustang Bio and City of Hope National Medical Center Patents and Patent Applications.....	175
Table 44 Noile-Immune Biotech Inc. Yamaguchi University Patent Applications .....	176
Table 45 Novartis AG and University of Pennsylvania Patents and Patent Applications, 2013-2018 .....	177
Table 46 Amgen Financials, 2014-2017 (\$ Millions) .....	186
Table 47 Amgen Financials, by Product, 2014-2017 (\$ Millions).....	186
Table 48 Avacta Group PLC Financials, 2015-2017 (\$ Millions).....	188
Table 49 Bellicum Pharmaceuticals Financials, 2014-2017 (\$ Millions) .....	190
Table 50 Bellicum Pharmaceuticals Key Switch Technologies.....	192
Table 51 Bluebird Bio Financials, 2014-2017 (\$ Millions) .....	193
Table 52 Celgene Corp. Financials, 2014-2017 (\$ Millions) .....	194
Table 53 Editas Medicine Financials, 2015-2017 (\$ Millions) .....	199
Table 54 Gilead Sciences Financials, 2014-2017 (\$ Millions).....	202
Table 55 Gilead Sciences Individual Product Sales, 2014-2017 (\$ Millions) .....	203
Table 56 Gilead Sciences Product Pipeline .....	204
Table 57 F. Hoffman La Roche Financials, 2014-2017 (CHF Millions).....	207
Table 58 F. Hoffman La Roche Pharmaceutical Division Financials, 2014-2017 (CHF Millions) .....	207
Table 59 F. Hoffman La Roche Pharmaceutical Division Oncology Product Sales, 2014-2017 (CHF Millions) .....	208
Table 60 iCell Gene Therapeutics Product Development Pipeline .....	209
Table 61 Juno Therapeutics Financials, 2014-2016 (\$ Millions) .....	211
Table 62 Juno Therapeutics Product Pipeline.....	212
Table 63 Novartis AG Revenues, by Segment, 2015-2017 (\$ Millions).....	219
Table 64 Protheragen Enabling Technologies.....	223
Table 65 Shire Pharmaceuticals Financials, 2015-2017 (\$ Millions) .....	227
Table 66 Takeda Pharmaceuticals Financials, 2014-2016 (\$ Millions).....	228
Table 67 Company Addresses and Contact Details.....	232
Table 68 Government Regulatory Agencies and Professional Organizations Associated with CAR T-Cell Therapy .....	244
Table 69 Commonly Used Acronyms Associated with CAR T-Cell Therapy .....	249
Table 70 Recent Patent Applications Filed Related to CAR T-Cell Therapy .....	255
Table 71 CAR T-Cell and CD19 Clinical Trials in China.....	275

# List of Figures

Summary Figure A: Global CAR T-Cell Market Shares, by Region, 2018 (%).....	8
Summary Figure B: Global CAR T-Cell Market, by Product, 2017-2023 (\$ Millions).....	9
Summary Figure C Global CAR T-Cell Clinical Trials as of April 27, 2018, by Phase (Number) .....	11
Figure 1 Historical Development of CAR T-Cell Therapy.....	15
Figure 2 Cytotoxic T-Cell Activation and Action.....	21
Figure 3 Overview of Signal Transduction Pathways Involved in Apoptosis .....	22
Figure 4 Model for Th Differentiation from Naïve CD4+ T Cells .....	23
Figure 5 Diagram of Regulatory T-Cell, Effector T-Cells and Dendritic Cells Showing Putative Mechanisms of Suppression by Regulatory T-Cells.....	24
Figure 6 Interactions and Cross Talk Between Different Subsets of NKT Cells and Other Immune Cells in TME .....	29
Figure 7 Schematic of Adoptive Cell Transfer Therapies .....	31
Figure 8 Structure and function of the TCR .....	32
Figure 9 General Structure of a Chimeric Antigen Receptor .....	34
Figure 10 CAR T-Cell Design .....	36
Figure 11 CAR T-Cell Manufacture and Product Testing Process .....	43
Figure 12 Sleeping Beauty (SB) Transposon System Mechanism Schematic.....	51
Figure 13 piggyBac (PB) Transposon System “Cut and Paste” Mechanism Schematic .....	52
Figure 14 CRISPR/Cas9 System Mechanism Schematic .....	55
Figure 15 CAR T-Cell Clinical Trial Activity Globally, by Phase, as of April 27, 2018 (Number).....	62
Figure 16 CAR T-Cell Clinical Trial Activity Globally, by Study Start Date and Phase, 2005-April 27, 2018 (Number).....	63
Figure 17 Distribution Map of CAR T-Cell Clinical Trial Activity Globally, by Study Location/Country, as of April 26, 2018 (Number) .....	65
Figure 18 Distribution Map of CAR T-Cell Clinical Trial Activity in Europe, by Study Location/Country, as of April 26, 2018 (Number) .....	66
Figure 19 Distribution Map of Phase I CAR T-Cell Clinical Trial Activity Globally, by Study Location/Country, as of April 26, 2018 (Number) .....	67
Figure 20 Distribution Map of Phase II CAR T-Cell Clinical Trial Activity Globally, by Study Location/Country, as of April 26, 2018 (Number) .....	68
Figure 21 Distribution Map of Phase III CAR T-Cell Clinical Trial Activity Globally, by Study Location/Country, as of April 26, 2018 (Number) .....	69
Figure 22 CAR T-Cell Clinical Trials in the United States, by Study Start Date and Phase, 2006-April 30, 2018 (Number).....	74
Figure 23 Distribution of CAR T-Cell Clinical Trials in China, by Study Location/Region, as of April 26, 2018 (Number).....	76
Figure 24 CAR T-Cell Clinical Trials in China, by Study Start Date and Phase, 2006 Through April 30, 2018 (Number).....	77
Figure 25 Estimated World Cancer Incidence in Men and Women Combined, by Major Site, 2012 (%)... 90	
Figure 26 Global Estimated Cancer Incidence in Men, by Major Site, 2012 (%).....	92
Figure 27 Global Estimated Cancer Incidence in Women by Major Site, 2012 (%) .....	94
Figure 28 Global CAR T-Cell Market, by Product, 2017-2023 (\$ Millions) .....	106
Figure 29 Global CAR T-Cell Market Shares, by Region, 2018 (%) .....	107
Figure 30 Drug Discovery and Development Time Line.....	117
Figure 31 Mutual Recognition Procedure .....	121
Figure 32 Decentralized Procedure .....	123
Figure 33 Japan Drug Funding/Reimbursement Approval Procedure.....	125



Figure 34 The Chinese Healthcare System.....	127
Figure 35 Argentina: Regulatory Drug Approval Procedure Standard Review 120-240 Business Days* for Approval** .....	141
Figure 36 Current Structure of the Health Care Sector in Saudi Arabia .....	148
Figure 37 Bellicum Pharmaceuticals Inc. Product Pipeline .....	191
Figure 38 Cellectis Allogeneic CAR T Pipeline .....	197
Figure 39 Eureka Therapeutics Product Pipeline .....	200
Figure 40 Formula Pharmaceuticals Product Pipeline .....	201
Figure 41 Kite Pharma Inc. (a Subsidiary of Gilead Sciences Inc.) CAR and TCR Pipeline .....	214
Figure 42 Mustang Bio Research and Development Pipeline .....	217
Figure 43 Noile-Immune Biotech CAR Pipeline.....	218
Figure 44 Novartis Sales Prediction for Kymriah .....	220
Figure 45 Protheragen Product Pipeline.....	222
Figure 46 PureTech Health Immune System Pipeline.....	224



*About BCC Research*

## *About BCC Research*

With our unparalleled 45-year history, BCC Research provides comprehensive analysis of global market sizing, forecasting and industry intelligence, covering markets where advances in science and technology are improving the quality, standard and sustainability of businesses, economies and lives.

## *BCC Membership*

From market sizing and forecasts, to opportunity assessments and competitive analyses, our ever-expanding library gives you the data, insights and intelligence required to ensure your project is a success. Members benefit from ongoing, unlimited access to the category or collections of their choice, and most membership packages pay for themselves within two to three reports being accessed.

Did you buy this report? You may qualify to apply your purchase price towards a full membership. Call 866/285-7215 or e-mail [info@bccresearch.com](mailto:info@bccresearch.com) to request a demo.

## *BCC Custom Research*

Our experts provide custom research projects to those working to identify new markets, introduce new products, validate existing market share, analyze competition and assess the potential for products to impact existing markets. With impressive academic credentials and broad and deep knowledge of global industrial markets, our independent analysts and consultants develop the facts, figures, analysis and assessments to inform the decisions that will move your company ahead. Confidential inquiries to: [custom@bccresearch.com](mailto:custom@bccresearch.com) or 781/205-2429.

## DISCLAIMER

The information developed in this report is intended to be as reliable as possible at the time of publication and is of a professional nature. This information does not constitute managerial, legal or accounting advice, nor should it be considered as a corporate policy guide, laboratory manual or an endorsement of any product, as much of the information is speculative in nature. BCC Research and the author assume no responsibility for any loss or damage that might result from reliance on the reported information or from its use.

ISBN: 978-1-62296-811-4  
August 2018